Effects of FL treatment on host NK cells, donor T cell expansion, and GVHD
| Group . | Treatment . | Donor T cells (× 104/spleen) . | % survival (day 45) . | |
|---|---|---|---|---|
| FL . | αNK1.1 . | |||
| A | − | − | 117 ± 13 | NT |
| B | − | + | 238 ± 47* | 43 (n = 7) |
| C | + | − | 22 ± 10 | NT |
| D | + | + | 106 ± 8† | 88 (n = 8)† |
| Group . | Treatment . | Donor T cells (× 104/spleen) . | % survival (day 45) . | |
|---|---|---|---|---|
| FL . | αNK1.1 . | |||
| A | − | − | 117 ± 13 | NT |
| B | − | + | 238 ± 47* | 43 (n = 7) |
| C | + | − | 22 ± 10 | NT |
| D | + | + | 106 ± 8† | 88 (n = 8)† |
B6D2F1 mice received FL (10 μg/day, day − 9 to day − 2) and were treated with either 200 μg of anti-NK1.1 mAbs22 or diluent on days − 2 and − 1 and were then given 12 Gy TBI on day 0 and received transplants of 5 × 106 BM cells and 2.5 × 106 nylon wool–purified splenic T cells from B6.Ly-5a donors. Donor T-cell number was determined as CD45.1+ CD3+ cells by 2-color flow cytometric analysis of splenocytes on day 4 (3 mice/group). Data represent 1 of 2 similar experiments.
NT indicates not tested.
P < .05 compared to group A.
P < .05 compared to group B.